NEONC TECHNOLOGIES HOLDINGS, INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $1.91 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-10
- NEONC TECHNOLOGIES HOLDINGS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was $79.87K, a 98.51% decline year-over-year.
- NEONC TECHNOLOGIES HOLDINGS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was $5.37M.
- NEONC TECHNOLOGIES HOLDINGS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was -$26.85K.
- NEONC TECHNOLOGIES HOLDINGS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was -$6.16K, a 118.66% decline from fiscal 2024.
- NEONC TECHNOLOGIES HOLDINGS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was $33.03K.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.91M 10-Q · filed 2026-08-10 | |||
| 2026-03-31 | $79.87K 10-Q · filed 2026-05-15 | |||
| 2025-12-31 | -$6.16K 10-K · filed 2026-03-31 | |||
| 2025-09-30 | $1.45M 10-Q · filed 2025-11-14 | |||
| 2025-06-30 | $60.15K 10-Q · filed 2026-08-10 | |||
| 2025-03-31 | $5.37M 10-Q · filed 2026-05-15 | |||
| 2024-12-31 | $33.03K 10-K · filed 2026-03-31 | |||
| 2024-09-30 | $1.30M 10-Q · filed 2025-11-14 | |||
| 2024-06-30 | $1.50M 10-Q · filed 2025-08-18 | |||
| 2024-03-31 | -$26.85K 10-Q · filed 2025-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |